Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 abe...

詳細記述

保存先:
書誌詳細
出版年:Lancet Oncol
主要な著者: Farooqui, Mohammed Z H, Valdez, Janet, Martyr, Sabrina, Aue, Georg, Saba, Nakhle, Niemann, Carsten U, Herman, Sarah E M, Tian, Xin, Marti, Gerald, Soto, Susan, Hughes, Thomas E, Jones, Jade, Lipsky, Andrew, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Yuan, Constance, Lee, Yuh Shan, Pedersen, Lone B, Geisler, Christian H, Calvo, Katherine R, Arthur, Diane C, Maric, Irina, Childs, Richard, Young, Neal S, Wiestner, Adrian
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342187/
https://ncbi.nlm.nih.gov/pubmed/25555420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)71182-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料